Fig. 2: Time to reaching any progression milestone by stage at baseline among PPMI sporadic PD cohort. | npj Parkinson's Disease

Fig. 2: Time to reaching any progression milestone by stage at baseline among PPMI sporadic PD cohort.

From: Neuronal alpha-Synuclein Disease integrated staging system performance in PPMI, PASADENA, and SPARK baseline cohorts

Fig. 2: Time to reaching any progression milestone by stage at baseline among PPMI sporadic PD cohort.The alternative text for this image may have been generated using AI.

Interval-censored survival curves of progression-free survival stratified by stage at baseline among PPMI sporadic PD participants. Progression was defined as reaching any clinically meaningful milestone across any of six clinical domains (walking and balance, motor complications, cognition, autonomic dysfunction, functional dependence, activities of daily living). Median (95% CI) progression-free survival equaled 8.3 (6.2, 10.1) years, 5.9 (4.1, 6.0) years, and 2.4 (1.0, 4.0) years among participants with a baseline stage of 2B, 3, and 4, respectively. A generalized log-rank test indicated a significant difference across the survival curves (P < 0.0001).

Back to article page